Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Rating of "Hold" by Brokerages

Key Points

• Shares have a consensus broker rating of Hold from eight firms (1 sell, 3 hold, 4 buy), with an average 12‑month price objective of $6.75.
• Inovio reported quarterly EPS of $0.31, beating analysts' estimate of (−$0.37) by $0.68, though analysts still project a −1.06 EPS for the current fiscal year.
• INO opened at $1.14 with a market capitalization of $79.16 million and a 12‑month range of $1.03–$2.98; institutional investors own 26.79% of the stock and Raymond James recently increased its stake to 16,680 shares.

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) have been given a consensus recommendation of "Hold" by the eight ratings firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $6.75.

A number of research analysts have weighed in on INO shares. Wall Street Zen raised Inovio Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, March 14th. Oppenheimer reissued an "outperform" rating on shares of Inovio Pharmaceuticals in a report on Friday, March 13th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. MCF Advisors LLC purchased a new position in shares of Inovio Pharmaceuticals during the third quarter worth about $26,000. SG Americas Securities LLC purchased a new position in shares of Inovio Pharmaceuticals during the third quarter worth about $27,000. Stephens Inc. AR purchased a new position in shares of Inovio Pharmaceuticals during the third quarter worth about $32,000. Focus Partners Wealth purchased a new position in shares of Inovio Pharmaceuticals during the third quarter worth about $33,000. Finally, Raymond James Financial Inc. grew its holdings in shares of Inovio Pharmaceuticals by 4,396.0% during the third quarter. Raymond James Financial Inc. now owns 16,680 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 16,309 shares in the last quarter. Hedge funds and other institutional investors own 26.79% of the company's stock.

Inovio Pharmaceuticals Stock Up 3.6%

INO stock opened at $1.14 on Tuesday. The firm has a market capitalization of $79.16 million, a PE ratio of -0.68 and a beta of 1.43. Inovio Pharmaceuticals has a twelve month low of $1.03 and a twelve month high of $2.98. The stock has a 50-day simple moving average of $1.46 and a two-hundred day simple moving average of $1.77.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last posted its earnings results on Thursday, March 12th. The biopharmaceutical company reported $0.31 earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $0.68. On average, equities research analysts anticipate that Inovio Pharmaceuticals will post -1.06 EPS for the current fiscal year.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio's business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio's platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.